Caribou Biosciences, Inc. Deferred Revenue Recognized
Caribou Biosciences, Inc. (CRBU) reported Deferred Revenue Recognized of $1.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-13
- Caribou Biosciences, Inc. contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $1.00M, a 0.00% change year-over-year.
- Caribou Biosciences, Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was $1.00M, a 42.86% increase year-over-year.
- Caribou Biosciences, Inc. contract with customer, liability, revenue recognized for the quarter ending 2024-03-31 was $700.00K, a 36.36% decline year-over-year.
- Caribou Biosciences, Inc. contract with customer, liability, revenue recognized for the quarter ending 2023-03-31 was $1.10M, a 83.33% increase year-over-year.
- Caribou Biosciences, Inc. contract with customer, liability, revenue recognized for fiscal 2025 was $2.80M, a 3.45% decline from fiscal 2024.
- Caribou Biosciences, Inc. contract with customer, liability, revenue recognized for fiscal 2024 was $2.90M, a 87.50% decline from fiscal 2023.
- Caribou Biosciences, Inc. contract with customer, liability, revenue recognized for fiscal 2023 was $23.20M, a 364.00% increase from fiscal 2022.
- Caribou Biosciences, Inc. contract with customer, liability, revenue recognized for fiscal 2022 was $5.00M, a 4900.00% increase from fiscal 2021.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.90M 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $1.00M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $2.80M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $2.50M 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $1.80M 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | $1.00M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $2.90M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $2.20M 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $1.60M 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | $700.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $23.20M 10-K · filed 2025-03-10 | |||
| 2023-09-30 | $23.20M 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $2.40M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | $1.10M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $5.00M 10-K · filed 2024-03-11 | |||
| 2022-09-30 | $3.40M 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | $2.50M 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | $600.00K 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $100.00K 10-K · filed 2023-03-09 | |||
| 2021-09-30 | $100.00K 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $100.00K 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | $100.00K 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $700.00K 10-K · filed 2022-03-21 | |||
| 2020-09-30 | $1.00M 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | $900.00K 10-Q · filed 2021-09-02 | |||
| 2019-12-31 | $1.80M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |